Expert Interview
Second View: Discussing new data from Phase II trial on Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced metastatic gastro-oesophageal adenocarcinoma (mGEA)
Ticker(s): JAZZInstitution: Humanitas Research Hospital
- an oncologist with a specialized focus on gastrointestinal tract cancers, I routinely manage patients with gastric cancer anI would be delighted to engage in a discussion regarding the findings of the RATIONALE-305 study.
Approximately 50 patients per month with gastric adenocarcinoma or gastroesophageal junction adenocarcinoma are under my care.
I am well-acquainted with the first-line chemotherapy and anti-PD-1 treatment, which includes Tislelizumab, and am prepared to discuss the ESMO abstract from the final analysis of the RATIONALE-305 study.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
